The specified drug use result surveillance of mogamulizumab in patients with CCR4 positive relapsed or refractory peripheral T-cell lymphoma, and relapsed or refractory cutaneous T-cell lymphoma

The specified drug use result surveillance of mogamulizumab in patients with CCR4 positive relapsed or refractory peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma - The specified drug use result surveillance of mogamulizumab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048043

Enrollment

150

Registered

2022-06-13

Start date

2014-04-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CCR4 positive relapsed or refractory peripheral T-cell lymphoma, and relapsed or refractory cutaneous T-cell lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have CCR4 positive relapsed or refractory peripheral T-cell lymphoma, and relapsed or refractory cutaneous T-cell lymphoma, and were treated with mogamulizumab

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
1.Safety (1)Occurrence of ADRs (e.g., types and incidence) (2)Evaluation on factors likely to affect safety (3)Occurrence of serious adverse events (4)Occurrence of priority survey items (infusion-related reactions, skin disorders, infections and immune disorders associated with hematological toxicity, tumor lysis syndrome, and interstitial lung disease) 2.Efficacy (1)Response rate (by attending physician) (2)Survival rate at 31 weeks after treatment initiation	—

Measure

Time frame

1.Safety (1)Occurrence of ADRs (e.g., types and incidence) (2)Evaluation on factors likely to affect safety (3)Occurrence of serious adverse events (4)Occurrence of priority survey items (infusion-related reactions, skin disorders, infections and immune disorders associated with hematological toxicity, tumor lysis syndrome, and interstitial lung disease) 2.Efficacy (1)Response rate (by attending physician) (2)Survival rate at 31 weeks after treatment initiation

—

Countries

Japan

Contacts

Public ContactYukie Tsuji

Kyowa Kirin Co., Ltd. Pharmacovigilance Department

yukie.tsuji.dq@kyowakirin.com070-3143-7893

Outcome results